Search Results - "KHAYAT, David"

Delivering affordable cancer care in high-income countries by Sullivan, Richard, Prof, Peppercorn, Jeffrey, Prof, Sikora, Karol, Prof, Zalcberg, John, Prof, Meropol, Neal J, Prof, Amir, Eitan, MBChB, Khayat, David, MD, Boyle, Peter, Prof, Autier, Philippe, PhD, Tannock, Ian F, Prof, Fojo, Tito, MD, Siderov, Jim, MClinPharm, Williamson, Steve, MRPharmS, Camporesi, Silvia, PhD, McVie, J Gordon, Prof, Purushotham, Arnie D, Prof, Naredi, Peter, Prof, Eggermont, Alexander, Prof, Brennan, Murray F, Prof, Steinberg, Michael L, Prof, De Ridder, Mark, Prof, McCloskey, Susan A, MD, Verellen, Dirk, Prof, Roberts, Terence, MD, Storme, Guy, Prof, Hicks, Rodney J, Prof, Ell, Peter J, Prof, Hirsch, Bradford R, MD, Carbone, David P, Prof, Schulman, Kevin A, Prof, Catchpole, Paul, PhD, Taylor, David, Prof, Geissler, Jan, PhD, Brinker, Nancy G, Meltzer, David, Prof, Kerr, David, Prof, Aapro, Matti, Prof

“…Summary The burden of cancer is growing, and the disease is becoming a major economic expenditure for all developed countries. In 2008, the worldwide cost of…”
Get full text

6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial by Pivot, Xavier, Prof, Romieu, Gilles, MD, Debled, Marc, MD, Pierga, Jean-Yves, Prof, Kerbrat, Pierre, Prof, Bachelot, Thomas, MD, Lortholary, Alain, MD, Espié, Marc, MD, Fumoleau, Pierre, Prof, Serin, Daniel, MD, Jacquin, Jean-Philippe, MD, Jouannaud, Christelle, MD, Rios, Maria, MD, Abadie-Lacourtoisie, Sophie, MD, Tubiana-Mathieu, Nicole, Prof, Cany, Laurent, MD, Catala, Stéphanie, MD, Khayat, David, Prof, Pauporté, Iris, PhD, Kramar, Andrew, PhD

“…Summary Background Since 2005, 12 months of adjuvant trastuzumab has been the standard treatment for patients with HER2-positive early-stage breast cancer…”
Get full text

Comprehensive analysis of long non-coding RNAs in human breast cancer clinical subtypes by Su, Xiaoping, Malouf, Gabriel G, Chen, Yunxin, Zhang, Jianping, Yao, Hui, Valero, Vicente, Weinstein, John N, Spano, Jean-Philippe, Meric-Bernstam, Funda, Khayat, David, Esteva, Francisco J

“…Accumulating evidence highlights the potential role of long non-coding RNAs (lncRNAs) as biomarkers and therapeutic targets in solid tumors. However, the role…”
Get full text

Comprehensive integrative profiling of upper tract urothelial carcinomas by Su, Xiaoping, Lu, Xiaofan, Bazai, Sehrish Khan, Compérat, Eva, Mouawad, Roger, Yao, Hui, Rouprêt, Morgan, Spano, Jean-Philippe, Khayat, David, Davidson, Irwin, Tannir, Nizar N, Yan, Fangrong, Malouf, Gabriel G

“…Crosstalk between genetic, epigenetic, and immune alterations in upper tract urothelial carcinomas and their role in shaping muscle invasiveness and patient…”
Get full text

Randomized Phase III Trial Comparing Biweekly Infusional Fluorouracil/Leucovorin Alone or With Irinotecan in the Adjuvant Treatment of Stage III Colon Cancer: PETACC-3 by VAN CUTSEM, Eric, LABIANCA, Roberto, MINI, Enrico, GREIL, Richard, DI COSTANZO, Francesco, COLLETTE, Laurence, CISAR, Laura, XIAOXI ZHANG, KHAYAT, David, BOKEMEYER, Carsten, ROTH, Arnaud D, CUNNINGHAM, David, BODOKY, György, BARONE, Carlo, ARANDA, Enrique, NORDLINGER, Bernard, TOPHAM, Claire, TABERNERO, Josep, ANDRE, Thierry, SOBRERO, Alberto F

“…PURPOSE The primary objective of this randomized, multicenter, phase III trial was to investigate whether the addition of irinotecan to the de Gramont…”
Get full text

Phase 1b Study of Dulanermin (recombinant human Apo2L/TRAIL) in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Patients With Advanced Non-Squamous Non–Small-Cell Lung Cancer by Soria, Jean-Charles, Smit, Egbert, Khayat, David, Besse, Benjamin, Yang, Xinqun, Hsu, Cheng-Pang, Reese, David, Wiezorek, Jeffrey, Blackhall, Fiona

“…To determine the safety, pharmacokinetics (PK), and maximum-tolerated dose (MTD) up to a prespecified target dose of dulanermin in combination with paclitaxel,…”
Get full text

Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer by Cunningham, David, Humblet, Yves, Siena, Salvatore, Khayat, David, Bleiberg, Harry, Santoro, Armando, Bets, Danny, Mueser, Matthias, Harstrick, Andreas, Verslype, Chris, Chau, Ian, Van Cutsem, Eric

“…In this randomized trial, cetuximab, a monoclonal antibody against the epidermal growth factor receptor, was given alone or in combination with irinotecan to…”
Get full text

Next-Generation Sequencing of Translocation Renal Cell Carcinoma Reveals Novel RNA Splicing Partners and Frequent Mutations of Chromatin-Remodeling Genes by MALOUF, Gabriel G, XIAOPING SU, CAMPARO, Philippe, DOSS, Denaha J, THOMPSON, Erika J, KHAYAT, David, WOOD, Christopher G, YU, Willie, TEH, Bin T, WEINSTEIN, John, TANNIR, Nizar M, HUI YAO, JIANJUN GAO, LIANGWEN XIONG, QIUMING HE, COMPERAT, Eva, COUTURIER, Jérôme, MOLINIE, Vincent, ESCUDIER, Bernard

“…MITF/TFE translocation renal cell carcinoma (TRCC) is a rare subtype of kidney cancer. Its incidence and the genome-wide characterization of its genetic origin…”
Get full text

Integrated Multi-omic Analysis of Esthesioneuroblastomas Identifies Two Subgroups Linked to Cell Ontogeny by Classe, Marion, Yao, Hui, Mouawad, Roger, Creighton, Chad J., Burgess, Alice, Allanic, Frederick, Wassef, Michel, Leroy, Xavier, Verillaud, Benjamin, Mortuaire, Geoffrey, Bielle, Franck, Le Tourneau, Christophe, Kurtz, Jean-Emmanuel, Khayat, David, Su, Xiaoping, Malouf, Gabriel G.

“…Esthesioneuroblastoma (ENB) is a rare cancer of the olfactory mucosa, with no established molecular stratification to date. We report similarities of ENB with…”
Get full text

DNA Methylation Signature Reveals Cell Ontogeny of Renal Cell Carcinomas by Malouf, Gabriel G, Su, Xiaoping, Zhang, Jianping, Creighton, Chad J, Ho, Thai H, Lu, Yue, Raynal, Noël J-M, Karam, Jose A, Tamboli, Pheroze, Allanick, Frederick, Mouawad, Roger, Spano, Jean-Philippe, Khayat, David, Wood, Christopher G, Jelinek, Jaroslav, Tannir, Nizar M

“…DNA methylation is a heritable covalent modification that is developmentally regulated and is critical in tissue-type definition. Although genotype-phenotype…”
Get full text

Treatment for metastatic malignant melanoma: Old drugs and new strategies by Mouawad, Roger, Sebert, Marie, Michels, Judith, Bloch, Joel, Spano, Jean-Philippe, Khayat, David

“…Abstract The number of melanoma cases worldwide is increasing faster than any other cancer and remains one of the most treatment-refractory malignancies…”
Get full text

Outcomes after adjuvant chemotherapy in the treatment of high‐risk urothelial carcinoma of the upper urinary tract (UUT‐UC) by Vassilakopoulou, Maria, de la Motte Rouge, Thibault, Colin, Pierre, Ouzzane, Adil, Khayat, David, Dimopoulos, Meletios‐Athanasios, Papadimitriou, Christos A., Bamias, Aristotle, Pignot, Géraldine, Nouhaud, François Xavier, Hurel, Sophie, Guy, Laurent, Bigot, Pierre, Roumiguié, Mathieu, Rouprêt, Morgan

“…BACKGROUND: Urothelial carcinoma of the upper urinary tract (UUT‐UC) was a rare, aggressive urologic cancer with a propensity for multifocality, local…”
Get full text

Unique Transcriptomic Profile of Collecting Duct Carcinomas Relative to Upper Tract Urothelial Carcinomas and other Kidney Carcinomas by Malouf, Gabriel G., Compérat, Eva, Yao, Hui, Mouawad, Roger, Lindner, Veronique, Rioux-leclercq, Nathalie, Verkarre, Virginie, Leroy, Xavier, Dainese, Linda, Classe, Marion, Descotes, Jean-Luc, Barthelemy, Philippe, Yacoub, Mokrane, Rouprêt, Morgan, Bernhard, Jean-Christophe, Creighton, Chad J., Spano, Jean-Philippe, Su, Xiaoping, Khayat, David

“…Collecting duct carcinoma (CDC) is a kidney cancer subtype that is thought to arise from principal cells in distal parts of the collecting ducts. Some studies…”
Get full text

AIDS-Related Malignancies: State of the Art and Therapeutic Challenges by SPANO, Jean-Philippe, COSTAGLIOLA, Dominique, KATLAMA, Christine, MOUNIER, Nicolas, OKSENHENDLER, Eric, KHAYAT, David

“…Despite the impact of combination antiretroviral therapy (cART) on HIV-related mortality, malignancy remains an important cause of death in the current era…”
Get full text

Expression of long non-coding RNA MFI2-AS1 is a strong predictor of recurrence in sporadic localized clear-cell renal cell carcinoma by Flippot, Ronan, Mouawad, Roger, Spano, Jean-Philippe, Rouprêt, Morgan, Compérat, Eva, Bitker, Marc-Olivier, Parra, Jérôme, Vaessen, Christophe, Allanic, Frederick, Manach, Quentin, Tannir, Nizar M., Khayat, David, Su, Xiaoping, Malouf, Gabriel G.

“…Prediction of recurrence is a challenge for the development of adjuvant treatments in clear-cell renal cell carcinoma (ccRCC). In these tumors, expression of…”
Get full text

Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies by Ludwig, Heinz, Khayat, David, Giaccone, Giuseppe, Facon, Thierry

“…The proteasome is responsible for the degradation of intracellular proteins, including several involved in cell cycle control and the regulation of apoptosis…”
Get full text

Characterization of long non-coding RNA transcriptome in clear-cell renal cell carcinoma by next-generation deep sequencing by Malouf, Gabriel G., Zhang, Jianping, Yuan, Ying, Compérat, Eva, Rouprêt, Morgan, Cussenot, Olivier, Chen, Yunxin, Thompson, Erika J., Tannir, Nizar M., Weinstein, John N., Valero, Vicente, Khayat, David, Spano, Jean-Philippe, Su, Xiaoping

“…Introduction: Long non-coding RNA (lncRNA) have proven to play key roles in cell physiology from nuclear organization and epigenetic remodeling to…”
Get full text

Changing patient perceptions of the side effects of cancer chemotherapy by Carelle, Nadége, Piotto, Estelle, Bellanger, Agnés, Germanaud, Jerome, Thuillier, Alain, Khayat, David

“…BACKGROUND Quality‐of‐life (QoL) issues have become increasingly important as the number of newly diagnosed patients with cancer increases and survival…”
Get full text

Old and new serological biomarkers in melanoma: where we are in 2009 by Mouawad, Roger, Spano, Jean-Philippe, Khayat, David

“…Biomarkers play an important role in the diagnosis and prognostic classification of various cancers and can be useful in monitoring the patient's clinical…”
Get full text

Long-Term Survival in Gastroesophageal Junction Adenocarcinoma: Ramucirumab by Gil-Delgado, Maria Angeles, Lucidarme, Olivier, Bachet, Jean Baptiste, Mahi, Naima, Khayat, David

“…We report a case of long-term survival with complete response of liver metastases within RAINBOW, a randomized, controlled trial of ramucirumab 8 mg/kg…”
Get full text